CA
NZ
UK
AU
IND
US
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) has disclosed its financial results for the second quarter of 2026, marking a noteworthy $0.2 million in revenue. This figure represents the company's first revenue recognition, primarily driven by grant funding related to its proteoform assay development and sales …
Picard Medical, Inc. (NYSE American: PMI), the parent company of SynCardia Systems LLC, has secured a important reprieve for its continued listing on the NYSE American. The exchange accepted Picard Medical’s compliance plan, granting the company a pathway to rectify its financial and operational …
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) recorded a loss per share of $-0.05 for the quarter ended March 31, missing the consensus estimate of $-0.04. The company’s shares have risen markedly year‑to‑date, reflecting investor optimism despite the earnings shortfall. This performance comes as …
The acquisition brings Forte’s lead asset, the anti-CD122 antibody FB102, into argenx’s development stream, immediately expanding its therapeutic reach. Market participants reacted sharply as Forte’s stock surged 39%, underscoring investor optimism about the combined pipeline. The transaction, expected to close in the third quarter, …
The $1.50 per share price was set modestly above the closing price of the preceding trading session, reflecting a measured premium despite recent volatility in the stock. The proceeds are intended to support the company’s strategic initiatives.
FOXO Technologies Inc. trading under the ticker FOXO, is moving forward with a strategic purchase through its wholly‑owned entity, Vector BioSource Inc. The transaction involves the acquisition of four U.S. The agreement outlines an upfront cash payment of $3,500,000 and provides for an additional …
Gossamer Bio (NASDAQ: GOSS) has secured a $5 million cash settlement from Chiesi, ending their 2024 collaboration and granting the company exclusive worldwide development and commercialization rights to seralutinib. The agreement terminates the prior license that divided U.S. profits with Chiesi, bringing all future …
Philips showed stronger than expected earnings performance for the second quarter of 2026, highlighting its capacity to meet market demands. Despite the company’s success in exceeding earnings predictions, investor reaction was tepid, resulting in a decline in share prices. This paradoxical situation points to …
MapLight Therapeutics posted an earnings per share of -1.34 for the quarter, missing the -1.12 consensus forecast. The miss coincided with the company's presentation of top-line results from its recent trial in schizophrenia, which offered mixed signals on efficacy. Despite the earnings disappointment, the …
The latest clinical data from ORYZON Genomics highlights significant advancements in cancer treatment, particularly for acute myeloid leukemia (AML). The company reported a remarkable 100% overall response rate (ORR) for its leading drug, iadademstat, when used in conjunction with azacitidine and venetoclax. Such compelling …
Please wait processing your request...